Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2025-07-14 am EDT			After hours 01:46:33 pm
83.54 ^EUR	+0.61%		84.30	+0.90%

Jul. 11	SANOFI : UBS reiterates its Buy rating	ZD
Jul. 10	Delaware Supreme Court sides with Zantac drugmakers over cancer evidence	RE

US Senators Introduce Bill to Ban Direct-to-Consumer Drug Ads

Published on 06/12/2025 at 13:52

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sanofi

SANOFI : UBS reiterates its Buy rating	Jul. 11	ZD
Delaware Supreme Court sides with Zantac drugmakers over cancer evidence	Jul. 10	RE
Delaware Supreme Court sides with Zantac drugmakers over evidence	Jul. 10	RE
Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket	Jul. 10	MT
SANOFI : UBS maintains a Buy rating	Jul. 08	ZD
SANOFI : Goldman Sachs reiterates its Neutral rating	Jul. 03	ZD
Berenberg Keeps Sanofi at Buy on Expanding Pipeline Optionality	Jul. 03	MT
SANOFI : Gets a Buy rating from Berenberg	Jul. 03	ZD
AlphaValue/Baader Europe Cuts Sanofi Price Target Amid Pipeline Setbacks, Leadership Concerns	Jul. 02	MT
SANOFI : Barclays keeps its Buy rating	Jul. 02	ZD
SANOFI : JP Morgan remains Neutral	Jul. 02	ZD
SANOFI : Pipeline disappointments may push out the CEO	Jul. 01
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	Jul. 01	MT
Adagene ADRs Rise Following Sanofi Investment	Jul. 01	DJ
Adagene to Receive up to $25 Million Investment From Sanofi; Shares up Pre-Bell	Jul. 01	MT
SANOFI : UBS reaffirms its Buy rating	Jul. 01	ZD
Euroapi: sells Haverhill site in UK	Jul. 01	CF
Esteve Pharmaceuticals, S.A. agreed to acquire Caprelsa® rights in more than 50 countries from Sanofi.	Jun. 30	CI
Sanofi Advances Rare Neurological Disorder Treatment with Orphan Drug Status in Japan	Jun. 30	MT
Sanofi Announces Riliprubart Granted Orphan Drug Designation in Japan for Chronic Inflammative Demyelinating Polyneuropathy	Jun. 30	CI
Sanofi: riliprubart designated orphan drug in Japan	Jun. 30	CF
Sanofi's Riliprubart Secures Orphan Drug Designation in Japan	Jun. 30	MT
Kennedy's US vaccine panel backs preservative-free shot despite safety evidence	Jun. 26	RE
Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies	Jun. 26	RE
US CDC vaccine panel postpones vote on RSV therapies	Jun. 25	RE

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2024, the group had 52 production sites worldwide. In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation. Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).

Employees

82,878

Sector

Pharmaceuticals

Calendar

Jul. 31 - Q2 2025 Earnings Release

More about the company